DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for chronic granulomatous disease — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic granulomatous disease maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chronic granulomatous disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neutrophil cytosolic factor 4 (NCF4) — NCF4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet butanoyloxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1H6H · 1.7 Å · ligand 2-(BUTANOYLOXY)-1-{[(HYDROXY{[2,3,4,6-TETRAHYDROXY-5-(PHOSPHONOOXY)CYCLOHEXYL]OXY}PHOSPHORYL)OXY]METHYL}ETHYL
BUTANOATE (PIB). Experimental structure, not a prediction.
What the evidence adds up to
In 1982 a 14-year-old boy with chronic granulomatous disease was described who, under long-term prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX), remained practically infection-free. The clinical behaviour, laboratory findings and genetic pattern in that patient suggested a variant of CGD that combined elements of the childhood form with elements more characteristic of the adulthood form. The report is a single case, not a controlled trial, and no other patients were treated.
Two other abstracts are available but do not concern chronic granulomatous disease treatment. One from 2016 reviews histologic features of granulomatous skin diseases generally, noting that in infections a granuloma forms when an agent cannot be eliminated by the immune system; typical agents include mycobacteria, fungal infections such as histoplasmosis, and parasites such as leishmaniasis. The other from 1960 describes granulomatous orchitis, a condition of the testis, with no mention of CGD.
No controlled studies, no randomised trials, and no data on survival or response rates for any drug in chronic granulomatous disease are provided in these abstracts. What is missing is any systematic evidence: no trial design, no patient stratification, and no funding for a proper study of TMP-SMX or any other agent in CGD.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2016 · 29 citations · open access
Histologic features of granulomatous skin diseases
AbstractGranulomatous disorders affecting the skin belong to a heterogeneous group of diseases, which were predominantly classified based on pathogenetic features. In infections diseases a granuloma is formed if an agent could not be eliminated by the immune system. Typical agents which cause granulomatous reactions are mycobacteria, fungal infections, especially extra European agent, which could effect the skin by, dissemination (e.g. histoplasmosis) or parasites, like leishmaniasis.
American Journal of Clinical Pathology · 1960 · 9 citations
Granulomatous Orchitis
AbstractJournal Article Granulomatous Orchitis Get access T. H. Capers T. H. Capers Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 34, Issue 2, 1 August 1960, Pages 139–145, https://doi.org/10.1093/ajcp/34.2.139 Published: 01 August 1960 Article history Received: 16 January 1960 Revision received: 01 April 1960 Accepted: 13 April 1960 Published: 01 August 1960
CHRONIC GRANULOMATOUS DISEASE: A NEW CLINICAL VARIANT
AbstractABSTRACT. We describe a 14‐year‐old boy who suffered from chronic granulomatous disease (CGD). Long‐term prophylactic treatment with trimethoprimsulfamethoxasole (TMP‐SMX) has succeeded to maintain the patient practically infection‐free. The clinical behavior, the laboratory findings and the genetic pattern of CGD in this patient suggest a variant of the disease, consisting of a combination of elements which pertain to the “childhood” form, with others which are more characteristic of the “adulthood” form of the syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
